Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743
Solange Peters, Arnaud Scherpereel, Robin Cornelissen, et al.
Annals of Oncology (2022) Vol. 33, Iss. 5, pp. 488-499
Open Access | Times Cited: 185

Showing 1-25 of 185 citing articles:

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227
Julie R. Brahmer, Jong-Seok Lee, Tudor‐Eliade Ciuleanu, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 6, pp. 1200-1212
Open Access | Times Cited: 204
Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications
Lin-Yong Zhao, Jia-Xin Mei, Gang Yu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 150
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Kevin J. Harrington, Robert L. Ferris, Maura L. Gillison, et al.
JAMA Oncology (2023) Vol. 9, Iss. 6, pp. 779-779
Open Access | Times Cited: 45
Cold and hot tumors: from molecular mechanisms to targeted therapy
Bo Wu, Bo Zhang, Bowen Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 35
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial
David P. Carbone, Tudor‐Eliade Ciuleanu, Michael Schenker, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 2, pp. e008189-e008189
Open Access | Times Cited: 33
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Weishi Cheng, Kai Kang, Ailin Zhao, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 25
Treatment of Pleural Mesothelioma: ASCO Guideline Update
Hedy L. Kindler, Nofisat Ismaila, Lyudmila Bazhenova, et al.
Journal of Clinical Oncology (2025) Vol. 43, Iss. 8, pp. 1006-1038
Closed Access | Times Cited: 3
Leveraging Immunogenic Cell Death to Enhance the Immune Response against Malignant Pleural Mesothelioma Tumors
Meng Rui Chang, Egor M. Matnurov, Chengnan Wu, et al.
Journal of the American Chemical Society (2025) Vol. 147, Iss. 9, pp. 7908-7920
Open Access | Times Cited: 2
First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations
Luís Paz-Ares, Tudor‐Eliade Ciuleanu, Manuel Cobo, et al.
Journal of Thoracic Oncology (2022) Vol. 18, Iss. 2, pp. 204-222
Open Access | Times Cited: 68
Immunotherapy approaches for malignant pleural mesothelioma
Dean A. Fennell, Sean Dulloo, James Harber
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 9, pp. 573-584
Closed Access | Times Cited: 42
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial
Quincy Chu, Federica Perrone, Laurent Greillier, et al.
The Lancet (2023) Vol. 402, Iss. 10419, pp. 2295-2306
Closed Access | Times Cited: 33
Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy
Muhua Chen, Lei Bie, Ying Jieer
Biomedicine & Pharmacotherapy (2023) Vol. 167, pp. 115514-115514
Open Access | Times Cited: 23
Malignant Pleural Mesothelioma: A Comprehensive Review
Molly S Jain, Morgan Kay Crites, Patricia Rich, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 19, pp. 5837-5837
Open Access | Times Cited: 11
Targeting of focal adhesion kinase enhances the immunogenic cell death of PEGylated liposome doxorubicin to optimize therapeutic responses of immune checkpoint blockade
Baoyuan Zhang, Ning Li, Jiaming Gao, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 10
Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison
Linyan Cheng, Lujun Chen, Yuan Shi, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 8
A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab, as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13 18 BEAT-meso trial
Enriqueta Felip, Sanjay Popat, Urania Dafni, et al.
Annals of Oncology (2025)
Closed Access | Times Cited: 1
Safety of combining biologics in severe asthma: Asthma‐related and unrelated combinations
Marek Lommatzsch, Hendrik Suhling, Stephanie Korn, et al.
Allergy (2022) Vol. 77, Iss. 9, pp. 2839-2843
Open Access | Times Cited: 32
Immunotherapies in rare cancers
Sneha Vivekanandhan, Deborah Bahr, Ashish Kothari, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 21
Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date
Marzieh Nikoo, Fatemeh Rabiee, Hossein Mohebbi, et al.
International Immunopharmacology (2023) Vol. 117, pp. 109881-109881
Closed Access | Times Cited: 17
EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers
Marco Tagliamento, Marie Morfouace, Charalambos Loizides, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 7
Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04–2021) trial
O. Bylicki, Florian Guisier, Arnaud Scherpereel, et al.
Lung Cancer (2024) Vol. 194, pp. 107866-107866
Open Access | Times Cited: 6
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
Ramaswamy Govindan, Charu Aggarwal, Scott Antonia, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 5, pp. e003956-e003956
Open Access | Times Cited: 26
A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Hyun‐Sung Lee, Hee-Jin Jang, Maheshwari Ramineni, et al.
Clinical Cancer Research (2022) Vol. 29, Iss. 3, pp. 548-559
Open Access | Times Cited: 25
Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress
Matteo Perrino, Fabio De Vincenzo, Nadia Cordua, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 13
Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma—RIOMeso
Nicholas McNamee, Catriona Harvey, Lauren Gray, et al.
Journal of Thoracic Oncology (2023) Vol. 19, Iss. 4, pp. 636-642
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top